^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Renal Cell Carcinoma |
| Drug: | ALLO-316 (CD70-targeted CAR-T immunotherapy) |
| Direction: | Sensitive |
Evidence:
Title:
Allogene Therapeutics Receives FDA Fast Track Designation for its First Solid Tumor Candidate, ALLO-316 in the Treatment of Renal Cell Carcinoma
Published date:
03/10/2022
Excerpt:
...Allogene Therapeutics, Inc....announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation (FTD) to ALLO-316, the Company’s first AlloCAR T solid tumor clinical candidate for the treatment of patients with advanced or metastatic clear cell renal cell carcinoma (RCC). The FDA granted FTD based on the potential of ALLO-316 to address the unmet need for patients with difficult to treat renal cell carcinomas (RCC) who have failed standard RCC therapies.
